1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014

  • January 2014
  • -
  • Global Markets Direct
  • -
  • 67 pages

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA). Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Systemic Juvenile Idiopathic Arthritis (SJIA).
- A review of the Systemic Juvenile Idiopathic Arthritis (SJIA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Systemic Juvenile Idiopathic Arthritis (SJIA).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Systemic Juvenile Idiopathic Arthritis (SJIA) Overview 6
Pipeline Products for Systemic Juvenile Idiopathic Arthritis (SJIA) - Overview 7
Pipeline Products for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis 8
Systemic Juvenile Idiopathic Arthritis (SJIA) - Therapeutics under Development by Companies 9
Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Systemic Juvenile Idiopathic Arthritis (SJIA) - Products under Development by Companies 13
Systemic Juvenile Idiopathic Arthritis (SJIA) - Companies Involved in Therapeutics Development 14
Bristol-Myers Squibb Company 14
Johnson and Johnson 15
Biocon Limited 16
Italfarmaco S.p.A. 17
Avesthagen Limited 18
Systemic Juvenile Idiopathic Arthritis (SJIA) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Assessment by Therapeutic Class 28
Drug Profiles 31
abatacept - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
golimumab - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
givinostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
etanercept biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
adalimumab biosimilar - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Systemic Juvenile Idiopathic Arthritis (SJIA) - Recent Pipeline Updates 41
Systemic Juvenile Idiopathic Arthritis (SJIA) - Dormant Projects 50
Systemic Juvenile Idiopathic Arthritis (SJIA) - Product Development Milestones 51
Featured News and Press Releases 51
Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis 51
Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris 52
May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis 53
Jan 17, 2013: AbbVie Receives CHMP Positive Opinion For Humira 54
Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting 56
Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Abbott's Humira 57
Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012 59
May 29, 2012: Abbott To Present Clinical Data On HUMIRA At Annual Meeting Of European League Against Rheumatism 61
Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis 63
Sep 28, 2011: Abbott Japan And Eisai Announce Launch Of Humira Prefilled Syringe 20mg/0.4mL 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables

Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), H1 2014 7
Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 11
Comparative Analysis by Early Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Bristol-Myers Squibb Company, H1 2014 14
Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Johnson and Johnson, H1 2014 15
Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Biocon Limited, H1 2014 16
Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Italfarmaco S.p.A., H1 2014 17
Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Avesthagen Limited, H1 2014 18
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 21
Number of Products by Stage and Mechanism of Action, H1 2014 23
Number of Products by Stage and Route of Administration, H1 2014 25
Number of Products by Stage and Molecule Type, H1 2014 27
Number of Products by Stage and Therapeutic Class, H1 2014 30
Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Recent Pipeline Updates, H1 2014 41
Systemic Juvenile Idiopathic Arthritis (SJIA) - Dormant Projects, H1 2014 50

List of Figures

Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), H1 2014 7
Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 19
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23
Number of Products by Top 10 Route of Administration, H1 2014 24
Number of Products by Stage and Top 10 Route of Administration, H1 2014 25
Number of Products by Top 10 Molecule Type, H1 2014 26
Number of Products by Stage and Top 10 Molecule Type, H1 2014 27
Number of Products by Top 10 Therapeutic Class, H1 2014 28
Number of Products by Stage and Top 10 Therapeutic Class, H1 2014 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.